121 related articles for article (PubMed ID: 38109501)
1. Structure-Based Design of AG-946, a Pyruvate Kinase Activator.
Liu T; Padyana AK; Judd ET; Jin L; Hammoudeh D; Kung C; Dang L
ChemMedChem; 2024 Mar; 19(5):e202300559. PubMed ID: 38109501
[TBL] [Abstract][Full Text] [Related]
2. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.
Rab MAE; Van Oirschot BA; Kosinski PA; Hixon J; Johnson K; Chubukov V; Dang L; Pasterkamp G; Van Straaten S; Van Solinge WW; Van Beers EJ; Kung C; Van Wijk R
Haematologica; 2021 Jan; 106(1):238-249. PubMed ID: 31974203
[TBL] [Abstract][Full Text] [Related]
3. Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia.
Wang C; Chiarelli LR; Bianchi P; Abraham DJ; Galizzi A; Mattevi A; Zanella A; Valentini G
Blood; 2001 Nov; 98(10):3113-20. PubMed ID: 11698298
[TBL] [Abstract][Full Text] [Related]
4. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.
Kung C; Hixon J; Kosinski PA; Cianchetta G; Histen G; Chen Y; Hill C; Gross S; Si Y; Johnson K; DeLaBarre B; Luo Z; Gu Z; Yao G; Tang H; Fang C; Xu Y; Lv X; Biller S; Su SM; Yang H; Popovici-Muller J; Salituro F; Silverman L; Dang L
Blood; 2017 Sep; 130(11):1347-1356. PubMed ID: 28760888
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Yang H; Merica E; Chen Y; Cohen M; Goldwater R; Kosinski PA; Kung C; Yuan ZJ; Silverman L; Goldwasser M; Silver BA; Agresta S; Barbier AJ
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):246-259. PubMed ID: 30091852
[TBL] [Abstract][Full Text] [Related]
6. 3-Phosphoglycerate is an allosteric activator of pyruvate kinase from the hyperthermophilic archaeon Pyrobaculum aerophilum.
Solomons JT; Johnsen U; Schönheit P; Davies C
Biochemistry; 2013 Aug; 52(34):5865-75. PubMed ID: 23879743
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase Greensboro. A four-generation study of a high K0.5s (phosphoenolpyruvate) variant.
Valentine WN; Herring WB; Paglia DE; Steuterman MC; Brockway RA; Nakatani M
Blood; 1988 Sep; 72(3):1054-9. PubMed ID: 3416067
[TBL] [Abstract][Full Text] [Related]
8. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate.
Jurica MS; Mesecar A; Heath PJ; Shi W; Nowak T; Stoddard BL
Structure; 1998 Feb; 6(2):195-210. PubMed ID: 9519410
[TBL] [Abstract][Full Text] [Related]
9. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
10. Proton donor in yeast pyruvate kinase: chemical and kinetic properties of the active site Thr 298 to Cys mutant.
Susan-Resiga D; Nowak T
Biochemistry; 2004 Dec; 43(48):15230-45. PubMed ID: 15568816
[TBL] [Abstract][Full Text] [Related]
11. The lid domain is important, but not essential, for catalysis of Escherichia coli pyruvate kinase.
Sugrue E; Coombes D; Wood D; Zhu T; Donovan KA; Dobson RCJ
Eur Biophys J; 2020 Dec; 49(8):761-772. PubMed ID: 32978636
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate kinase isozyme (PK-Greenville) with defective allosteric activation by fructose-1,6-diphosphate: the role of F-1,6-P modulation in normal erythrocyte metabolism.
Paglia DE; Valentine WN; Holbrook CT; Brockway R
Blood; 1983 Nov; 62(5):972-9. PubMed ID: 6626748
[TBL] [Abstract][Full Text] [Related]
13. Purification and properties of aerobic and anoxic forms of pyruvate kinase from red muscle tissue of the channelled whelk, Busycotypus canaliculatum.
Plaxton WC; Storey KB
Eur J Biochem; 1984 Sep; 143(2):257-65. PubMed ID: 6468395
[TBL] [Abstract][Full Text] [Related]
14. Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study.
Fattizzo B; Vercellati C; Marcello A; Patel P; Wind-Rotolo M; Pettine L; Bonanomi M; Gaglio D; Bortolotti M; Leoni C; Fermo E; Bianchi P; Zaninoni A; Passamonti F; Barcellini W
Am J Hematol; 2024 Jun; 99(6):1201-1204. PubMed ID: 38563490
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate kinase hyperactivity genetically determined metabolic consequences and molecular characterization.
Max-Audit I; Rosa R; Marie J
Blood; 1980 Nov; 56(5):902-9. PubMed ID: 7426754
[TBL] [Abstract][Full Text] [Related]
16. Comparative kinetic studies on the L-type pyruvate kinase from rat liver and the enzyme phosphorylated by cyclic 3', 5'-AMP-stimulated protein kinase.
Ekman P; Dahlqvist U; Humble E; Engström L
Biochim Biophys Acta; 1976 Apr; 429(2):374-82. PubMed ID: 4127
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis, overexpression, and kinetic characterization of pyruvate kinase from methicillin-resistant Staphylococcus aureus.
Zoraghi R; See RH; Gong H; Lian T; Swayze R; Finlay BB; Brunham RC; McMaster WR; Reiner NE
Biochemistry; 2010 Sep; 49(35):7733-47. PubMed ID: 20707314
[TBL] [Abstract][Full Text] [Related]
18. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
Guan M; Tong Y; Liu X; Dong D; Zhou Y
Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate kinase of Streptococcus lactis.
Collins LB; Thomas TD
J Bacteriol; 1974 Oct; 120(1):52-8. PubMed ID: 4214503
[TBL] [Abstract][Full Text] [Related]
20. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
